As oligonucleotide therapeutics take center stage, bioanalysis has become critical to unlocking their promise. How do we ensure their safety, efficacy, and regulatory compliance? Dive into strategies for effective bioanalysis that can help advance the future of personalized medicine. https://hubs.li/Q036DdRK0 #oligos #oligonucleotides #drugdevelopment #precisionmedicine #bioanalysis
WuXi AppTec, Laboratory Testing Division
Pharmaceutical Manufacturing
Plainsboro, NJ 5,242 followers
Your success is our success.
About us
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated.“ Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).
- Website
-
https://labtesting.wuxiapptec.com/
External link for WuXi AppTec, Laboratory Testing Division
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Plainsboro, NJ
- Type
- Public Company
- Founded
- 1987
- Specialties
- ADME, DMPK, bioanalysis, drug metabolism, animal health, and agrochemical
Locations
-
Primary
Get directions
107 Morgan Lane
Plainsboro, NJ 08536, US
-
Get directions
6 Cedar Brook Dr
Cranbury, NJ 08512, US
Employees at WuXi AppTec, Laboratory Testing Division
-
Virginia Pate Whitaker
Associate Director, Laboratory Operations at WuXi AppTec
-
Kristin Peterson
Director, Business Development, Western US Region and APAC at WuXi AppTec
-
Keith Ciccaglione
Scientist II at WuXi AppTec, Laboratory Testing Division, New Jersey site
-
TJ Sigler
Executive Director, Head of International Sales & Marketing | Laboratory Testing Division at WuXi AppTec
Updates
-
We are proud to share our recent publication on TEAM-PCR, a groundbreaking technique enhancing the sensitivity of qPCR assays for the EGFR T790M mutation. This method could revolutionize how we approach mutation detection in clinical settings. Learn more about our findings: https://hubs.li/Q039hzrL0
-
Join our subject matter experts at the SOT Annual Meeting & ToxExpo in Orlando. We’ll be there March 17-19 at Booth 1133! We are hosting a pair of insightful sessions: Animal Disease Models in Ocular Drug Development Advances in Antibody Drug Conjugates: Overcoming Toxicology Challenges in Oncology Check out all of our posters on diverse topics, including preclinical immunotoxicity in Bama minipigs, siRNA formulation screening, intrathecal injection analyses, genotoxicity follow-up strategies, and more. Be sure to join us at our in-booth Happy Hour on Tuesday, 3/18, 3:00-4:30! Check here for full details, and we’ll see you in Orlando! https://hubs.li/Q038qp3P0
-
-
Four years ago, LNP-mRNA vaccines offered respite from the COVID-19 virus. Today, this novel drug modality is developing at a rapid pace. Explore the best strategies for the bioanalysis of LNP-mRNA products: #innovation #mRNA #vaccines https://hubs.li/Q035qR7t0
-
Oligonucleotide therapies (ONs), like siRNAs and ASOs, are at the forefront of modern medicine, offering hope for genetic, ophthalmic, and cardiovascular diseases. However, their interaction with the immune system poses unique challenges. From drug properties to delivery methods, every detail can impact immunogenicity. Our experts share strategies for analyzing and overcoming these hurdles in this comprehensive blog. Gain insights into: • Structural complexities of ONs. • Advances in delivery methods like lipid nanoparticles (LNPs). • Cutting-edge bioanalytical techniques, including electrochemiluminescence detection. Read more: https://hubs.li/Q037MR1J0 #Bioanalysis #Therapeutics #Innovation #Biopharma
-
Personalized medicine is revolutionizing healthcare by tailoring treatments to individual patients. Our latest article explores how bioanalysis is driving this innovation, enhancing treatment efficacy, and reducing adverse effects. Discover the future of healthcare today. https://hubs.li/Q039l5_J0 #PersonalizedMedicine #Bioanalysis #HealthcareInnovation #PrecisionTherapies
-
-
Small-molecule inhibitors, PROTACs, and molecular glues are just some of the new drugs emerging from small-molecule oncology research. However, developers must navigate complex regulatory hurdles to bring therapies to market as quickly and efficiently as possible. https://hubs.li/Q039gHdq0 #oncology #smallmoleculedrugs #drugresearch
-
Antibody-Drug Conjugates (ADCs) hold great promise, especially with reducing side effects and enhancing overall efficacy of treatment. To deliver on that promise, though, they need to be thoroughly tested. Here are 3 #DMPK strategies for ADC development: https://hubs.li/Q0360Pmn0
-
-
Proteolysis targeting chimera (PROTAC) drugs could offer hope to those suffering from several diseases, such as cancers and neurodegeneration. However, their unique structure, which gives them so much potential, also makes them difficult to develop. Read on to learn more about tackling issues with solubility, permeability and more. https://hubs.li/Q036x_-P0 #innovation #drugdevelopment #drugresearch
-
-
We’re looking forward to the SOT Annual Meeting & ToxExpo in Orlando March 16-20! Be sure to visit us at our Booth 1133, March 17-19. View our posters outlining research on topics including siRNA formulation screening, ROS assay validation, novel staining for in situ hybridization, systemic exposure in rabbits, spontaneous lesion studies in mice, and more. Attend our two enlightening sessions: Animal Disease Models in Ocular Drug Development Advances in Antibody Drug Conjugates: Overcoming Toxicology Challenges in Oncology Don’t miss our in-booth Happy Hour on Tuesday, 3/18, 3:00-4:30! Click here for all the details, and we’ll see you in Orlando! https://hubs.li/Q038qrY30
-